16 February 2023 - In 2022, EMA recommended 89 medicines for marketing authorisation. Of these, 411 had a new active substance which had never been authorised in the European Union before. 

The overview of the 2022 key recommendations published today includes figures on the authorisation of medicines and a selection of new treatments that represent significant progress in their therapeutic areas.

Read EMA press release